Login to Your Account



Study: D-Mab Delays Prostate Cancer Spread to Bones

By Donna Young


Wednesday, December 15, 2010
Catching Wall Street by surprise, Amgen Inc. reported top-line Phase III results showing Xgeva (denosumab) improved median bone metastasis-free survival by 4.2 months in men with castrate-resistant prostate cancer (CRPC) vs. placebo – the first time a bone-targeted drug has delayed the spread of prostate cancer to the bones.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription